Next-Generation Cancer Drug Rapalink-1 Found to Extend Lifespan in Yeast

Researchers at Queen Mary University of London have identified that the TOR-targeting cancer drug rapalink-1 can significantly extend the lifespan of fission yeast, a model organism used in biological studies. This finding, published in the journal *Communications Biology*, reveals a novel metabolic feedback loop involving the Target of Rapamycin (TOR) pathway, which is crucial for regulating growth and aging across various organisms, including humans. The study, led by Juhi Kumar, Kristal Ng, and Charalampos Rallis, highlights the potential of rapalink-1 not only as a cancer treatment but also as a contributor to longevity.

SciTechDaily

Rapalink-1 operates through TORC1, the growth-promoting component of the TOR pathway. The researchers discovered that this drug reduces certain growth aspects in yeast while simultaneously enhancing lifespan. A key element of this process involves agmatinases, enzymes that convert the metabolite agmatine into polyamines. The study indicates that these enzymes are integral to a newly identified metabolic feedback loop that regulates TOR activity. Disruption of agmatinase activity led to increased cell division but also accelerated signs of aging, suggesting a balance between immediate growth and long-term cellular health.

SciTechDaily

The findings suggest that the metabolic pathways influenced by agmatinases may be conserved in humans, indicating that dietary factors and gut microbiota could play significant roles in aging. Dr. Rallis noted, “By showing that agmatinases are essential for healthy aging, we’ve uncovered a new layer of metabolic control over TOR.” This research opens avenues for exploring how nutrition and microbial health can impact aging processes.

SciTechDaily

While agmatine supplements are commercially available, Dr. Rallis cautioned against their indiscriminate use for growth or longevity. He emphasized that the benefits of agmatine supplementation are contingent upon the integrity of specific metabolic pathways related to arginine breakdown. Furthermore, he warned that agmatine could also be linked to certain health issues, underscoring the need for careful consideration in its application.

SciTechDaily

The study's outcomes have significant implications for the fields of aging research, cancer biology, and metabolic diseases. They suggest new strategies that could integrate TOR-targeting drugs like rapalink-1 with dietary or microbial interventions to promote healthy aging.

SciTechDaily

• “By showing that agmatinases are essential for healthy aging, we’ve uncovered a new layer of metabolic control over TOR — one that may be conserved in humans,” — Dr. Charalampos Rallis, Researcher

SciTechDaily

• “ Rallis acknowledges that agmatine supplements are available in the market, but stresses: “We should be cautious about consuming agmatine for growth or longevity purposes.” — Dr. Charalampos Rallis, Researcher

SciTechDaily

This research marks a pivotal step in understanding the intersection of cancer treatment and longevity, potentially leading to innovative approaches in health and nutrition.

SciTechDaily